ChemoCentryx’s Return On Capital Employed Overview
Benzinga Pro data, ChemoCentryx (NASDAQ:CCXI) reported Q2 sales of $1.81 million. Earnings fell to a loss of $38.74 million, resulting in a 32.09% decrease from last quarter.
ChemoCentryx: Q2 Earnings Insights
Shares of ChemoCentryx (NASDAQ:CCXI) rose in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share fell 293.10% year over year to ($0.56), which missed the estimate of ($0.54).
ChemoCentryx Q3 EPS $(0.56) Down From $(0.35) YoY
ChemoCentryx (NASDAQ:CCXI) reported quarterly losses of $(0.56) per share. This is a 60 percent decrease over losses of $(0.35) per share from the same period last year.
Analyzing ChemoCentryx’s Unusual Options Activity
Shares of ChemoCentryx (NASDAQ:CCXI) saw some unusual options activity on Monday. Following the unusual option alert, the stock price moved down to $14.85.
Earnings Scheduled For August 9, 2021
Companies Reporting Before The Bell
• Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million.
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.
Analyzing ChemoCentryx’s Unusual Options Activity
On Friday, shares of ChemoCentryx (NASDAQ:CCXI) saw unusual options activity. After the option alert, the stock price moved down to $15.06.
Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates
The month of July was disappointing from the perspective of Food and Drug Administration decisions, as the agency handed down mostly negative verdicts.
The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix
Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow.